Sunday, January 17, 2021
Home Tags Sorrento’s TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies

Tag: Sorrento’s TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies

Sorrento’s TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123...

0
- Novel Anti-CD38 CAR-T and Anti-CD123 CAR-T Programs Utilizing Sorrento's Fully Human Antibodies Demonstrated Strong Anti-Tumor Activity in Preclinical Models of Multiple Myeloma and...
error: Sorry Content is protected !!